arrow
L

Lestat R. Ali

Harvard Medical School
H指数:15
被引数:1,532

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Dendritic cell redundancy enables priming of anti-tumor CD4+ T cells in pancreatic cancer

树突状细胞冗余性使胰腺癌中抗肿瘤CD4+ T细胞的初始激活成为可能

2026-05-070
OAAI
Scalable TCR synthesis and screening enable antigen reactivity mapping in vitiligo

可扩展的TCR合成和筛选使白癜风的抗原反应性作图

Immunity
IF26.3
2026-01-280
OAAI
Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancer

I期研究:评估ribociclib(CDK4/6抑制剂)联合sparatalizumab(PD-1抑制剂),并分别联用或未联用fulvestrant,用于激素受体阳性转移性乳腺癌或晚期卵巢癌。

2025-02-252
OA
PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with Pancreatic Cancer

PD-1阻断诱导胰腺癌患者以nf-κb信号为特征的非生产性T细胞反应的重新激活

2023-09-210
OAAI
cIAP1/2 Antagonism Induces Antigen-Specific T Cell-Dependent Immunity
2023-02-176
OA
cIAP1/2 antagonism eliminates MHC class I-negative tumors through T cell-dependent reprogramming of mononuclear phagocytes

cIAP1/2拮抗作用通过单核吞噬细胞的T细胞依赖性重编程消除MHC I类阴性肿瘤

2021-05-1936
OA
Inhibition of CDK4/6 Promotes CD8 T-cell Memory Formation
2021-05-0354
OA